Harvard Bioscience, Inc. (NASDAQ:HBIO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. “

Separately, ValuEngine lowered shares of Harvard Bioscience from a “hold” rating to a “sell” rating in a report on Friday, June 2nd.

Shares of Harvard Bioscience (HBIO) opened at 2.35 on Friday. The firm has a 50-day moving average price of $2.51 and a 200-day moving average price of $2.67. The stock’s market cap is $81.35 million. Harvard Bioscience has a 12 month low of $2.25 and a 12 month high of $3.30.

ILLEGAL ACTIVITY WARNING: This story was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/07/18/harvard-bioscience-inc-hbio-rating-lowered-to-hold-at-zacks-investment-research.html.

In related news, CEO Jeffrey Duchemin purchased 22,000 shares of the firm’s stock in a transaction on Monday, June 12th. The shares were bought at an average price of $2.76 per share, for a total transaction of $60,720.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Earl R. Lewis purchased 12,238 shares of the firm’s stock in a transaction on Thursday, May 25th. The stock was bought at an average price of $2.35 per share, for a total transaction of $28,759.30. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 52,950 shares of company stock worth $135,275. 8.80% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its position in shares of Harvard Bioscience by 5.9% in the first quarter. Renaissance Technologies LLC now owns 560,500 shares of the medical instruments supplier’s stock worth $1,457,000 after buying an additional 31,300 shares during the period. Dimensional Fund Advisors LP raised its position in Harvard Bioscience by 1.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,631,348 shares of the medical instruments supplier’s stock valued at $4,242,000 after buying an additional 20,499 shares during the last quarter. Royce & Associates LP raised its position in Harvard Bioscience by 2.9% in the first quarter. Royce & Associates LP now owns 1,557,600 shares of the medical instruments supplier’s stock valued at $4,050,000 after buying an additional 44,000 shares during the last quarter. Spark Investment Management LLC raised its position in Harvard Bioscience by 12.8% in the first quarter. Spark Investment Management LLC now owns 116,950 shares of the medical instruments supplier’s stock valued at $304,000 after buying an additional 13,250 shares during the last quarter. Finally, Algert Global LLC raised its position in Harvard Bioscience by 17.7% in the first quarter. Algert Global LLC now owns 113,818 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 17,120 shares during the last quarter. Institutional investors own 61.98% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Get a free copy of the Zacks research report on Harvard Bioscience (HBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.